A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at least six months lost an average of 12.9% of their body weight. The study highlights Tirzepatide’s potential as an effective off-label obesity treatment before its formal FDA approval for weight loss.